Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

First Published Online September 15, 2008
The Oncologist, Vol. 13, No. 9, 925-929, September 2008; doi:10.1634/theoncologist.2008-0133
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0133v1
13/9/925    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramsey, S.
Right arrow Articles by Scoggins, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramsey, S.
Right arrow Articles by Scoggins, J.

Commentary

Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology

Scott Ramseya,b, John Scogginsc

aFred Hutchinson Cancer Research Center, Seattle, Washington, USA; Departments of bMedicine and cHealth Services, University of Washington, Seattle, Washington, USA

Key Words. Cancer • Clinical trials • Registries • Publication bias

Correspondence: Scott D. Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M3-B232, PO Box 19024, Seattle, Washington 98109, USA. Telephone: 206-667-7846; Fax: 206-667-5977; e-mail: sramsey{at}fhcrc.org

Received June 13, 2008; accepted for publication June 30, 2008.

Disclosure: Employment/leadership position: None; Intellectual property rights/inventor/patent holder: None; Consultant/advisory role: None; Honoraria: None; Research funding: National Cancer Institute R25 CA 92408; Ownership interest: None; Expert testimony: None; Other: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers of the article.

Objective. Members of the International Committee of Medical Journal Editors require, as a condition of consideration for publication, that all clinical trials be registered in a public trials registry. We evaluated the proportion of registered trials that are published in the peer-reviewed literature.

Methods. After downloading the contents of the National Institutes of Health's ClinicalTrials.gov registry, we used key words to identify trials in oncology. We then evaluated the proportion of trials that had been published in journals listed in PubMed.gov. Among trials with published results, we determined the proportion that reported positive versus negative results.

Results. Among the 2,028 trials meeting the inclusion criteria, 17.6% were available in PubMed. Twenty-one percent of the trials registered before September 1, 2004 were published, compared with 11.9% of those registered after this date. Trials sponsored by clinical trial networks published the greatest proportion of registered studies (59.0%); studies sponsored by industry published the fewest (5.9%). Among published studies, 64.5% reported the results as positive findings.

Conclusions. Less than one in five studies in cancer that are registered with clinicaltrials.gov have been published in peer-reviewed journals. Research sponsors, researchers, and journal editors should redouble their efforts to encourage publication of registered clinical trials in oncology.




This article has been cited by other articles:


Home page
Arch Intern MedHome page
R. V. Luepker
Drug Safety: Are We Making Progress?: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"
Arch Intern Med, January 25, 2010; 170(2): 202 - 202.
[Full Text] [PDF]


Home page
BMJHome page
B. Goldacre
Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes
BMJ, November 27, 2009; 339(nov27_1): b4949 - b4949.
[Full Text]


Home page
The OncologistHome page
J. H. Doroshow
Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative
Oncologist, September 1, 2008; 13(9): 930 - 932.
[Full Text] [PDF]


Home page
The OncologistHome page
G. A. Curt and B. A. Chabner
One in Five Cancer Clinical Trials Is Published: A Terrible Symptom--What's the Diagnosis?
Oncologist, September 1, 2008; 13(9): 923 - 924.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.
Advertisement